Azitra Inc. develops clinical-stage precision dermatology therapies built around engineered proteins and topical live biotherapeutic products. Its pipeline includes ATR-12, an engineered S. epidermidis program for Netherton syndrome; ATR-04, an engineered S. epidermidis candidate for EGFR inhibitor-associated rash; and ATR-01, a program targeting ichthyosis vulgaris through delivery of recombinant human filaggrin.
Azitra news commonly covers patent protection, preclinical and clinical program updates, scientific presentations, business results, financing activity, shareholder meeting matters, and NYSE American listing-compliance notices. Company updates also reference its microbial discovery platform, artificial intelligence and machine-learning screening tools, and the use of genetically engineered bacteria and proteins for dermatology applications.
Azitra (AZTR) completed Cohort 1 of its ATR-04 Phase 1/2 trial and received safety committee clearance to proceed to Cohort 2. The committee reviewed available safety data from six patients, enabling enrollment and dosing in the second cohort.
The randomized, double-blind study evaluates topical ATR04-484 for skin toxicity associated with EGFR inhibitors, a type of cancer treatment, in adults. It compares safety, bioavailability, pharmacodynamics and preliminary efficacy against the vehicle, the formulation without the active treatment, using 3:1 randomization. Seven Cohort 1 patients received a single 4g application, followed by seven days of observation and once-daily application for 28 days. Azitra expects Cohort 2 to enroll approximately 24 patients, receiving 4g once daily for 28 days. The trial is running at six clinical sites.
Azitra (AZTR) will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026.
Co-founder and COO Travis Whitfill will share updates on Azitra's pipeline, including initial data from the ATR-COSF program for cosmetic applications and continued enrollment in the first cohort of the Phase 1/2 trial of ATR-04 for EGFR inhibitor-associated rash. A webcast of the prerecorded presentation will be available to conference participants.
Azitra (NYSE American: AZTR) announced it has received written notification from NYSE American that it has regained compliance with all continued listing standards set forth in Part 10 of the NYSE American Company Guide, resolving previously disclosed deficiencies under Sections 1003(a)(ii) and 1003(a)(iii).
As a result, the ".BC" below‑compliance indicator will no longer be disseminated and Azitra will be removed from NYSE American’s noncompliant issuers list. The company will remain subject to continued listing monitoring, and a repeat deficiency within 12 months could lead to truncated compliance procedures or immediate delisting proceedings.
Azitra (NYSE American: AZTR) reported Q2 2026 results and pipeline updates. R&D expenses were $1.4 million, flat year over year, while G&A rose to $2.1 million from $1.5 million. Net loss increased to $3.3 million versus $2.9 million in Q2 2025. Cash and cash equivalents were $6.7 million at June 30, 2026, up from $2.1 million at December 31, 2025.
Azitra reported first preclinical data for ATR-COSF, showing repeat-dose delivery, skin-layer targeting and anti-wrinkle activity in ex vivo human skin, with a cosmetic proof-of-concept study planned to start in Q3 2026. The company continued enrolling the first cohort in its Phase 1/2 trial of ATR-04 for EGFR inhibitor-associated rash, with topline data expected in Q4 2026, advanced recombinant protein programs (TEV Protease and T7 RNA Polymerase), and decided to pause further enrollment in the ATR-12 Phase 1b Netherton syndrome trial to prioritize capital.
Azitra (NYSE American: AZTR) reported new ex vivo human skin data for its ATR-COSF cosmetic program, a supernatant from engineered S. epidermidis that secretes a recombinant human filaggrin domain (rHDfilaggrin). Multiple-dose experiments in TH2-stimulated healthy skin explants showed increased rHDfilaggrin penetration through the stratum corneum into the stratum granulosum versus prior single-dose work, with higher concentrations when formulated as a 2% lyophilized hydrogel compared with concentrated supernatant alone.
In a second ex vivo model using defatted human skin, ATR-COSF hydrogels containing 0.09–7.5% (w/w) supernatant increased elasticity in a dose-dependent manner, from 1.6-fold to 4.4-fold. A 0.28% (w/w) formulation restored elasticity to levels historically observed in healthy skin, and a 0.3% (w/w) sample showed about twice the elasticity of placebo. Safety testing found the 2% supernatant hydrogel non-irritating and non-corrosive to skin and eyes, supporting its potential as a high-value anti-wrinkle cosmetic ingredient, according to Azitra.
Azitra (NYSE American: AZTR) reported corrected, detailed results from two ex vivo human skin tissue studies for its ATR-COSF cosmetic program, a supernatant formulation containing recombinant human filaggrin domain (rHDfilaggrin) derived from engineered S. epidermidis.
In a repeat‑dose model on TH2‑stimulated healthy skin explants, a 2% lyophilized supernatant hydrogel showed increasing rHDfilaggrin penetration from the stratum corneum into the stratum granulosum with additional applications and was classified as non‑irritating and non‑corrosive to skin and eyes. A second ex vivo model using defatted abdominoplasty skin showed dose‑dependent elasticity gains: 0.09% w/w active increased elasticity 1.6‑fold, 7.5% w/w increased it 4.4‑fold, and 0.28% w/w restored elasticity to levels historically seen in healthy skin. According to Azitra, these data support ATR-COSF’s potential as a high‑value cosmetic ingredient and will inform formulation optimization ahead of a planned human study.
Azitra (NYSE American: AZTR) CEO outlined a strategic reorientation toward programs with nearer-term value milestones, backed by a March 2026 financing of $10.5 million plus up to $21 million from warrant exercises.
Key moves include launching the ATR-COSF cosmetic filaggrin initiative, new recombinant protein programs, continued ATR-04 enrollment, and pausing ATR-12 enrollment to conserve capital, with multiple potential partnering or commercialization opportunities from 2026 onward.
Azitra (NYSE American: AZTR) will present at the 2026 BIO International Convention in San Diego. Cofounder and COO Travis Whitfill, Ph.D., MPH will speak on June 23, 2026, at 4:45 PM PT.
The presentation will cover pipeline progress, including ATR-12 and ATR-04 programs, and a new filaggrin-based protein and peptide initiative for cosmetic and cosmeceutical markets.
Azitra (NYSE American: AZTR) adjourned its 2026 Annual Meeting, first convened June 4, 2026, due to lack of quorum, with only about 17% of eligible shares represented versus the required 33 1/3%. The meeting will reconvene virtually on June 15, 2026, at 11:00 a.m. ET via proxydocs.com/AZTR.
Azitra (NYSE American: AZTR) plans to open its 2026 annual stockholder meeting on June 4, 2026, then immediately adjourn and reconvene it on June 15, 2026 at 11:00 a.m. Eastern Time in virtual format.
The adjournment allows extra time for stockholders of record on April 24, 2026 to receive and submit proxies via mail, internet, telephone, or during the reconvened webcast at www.proxydocs.com/AZTR. Previously submitted proxies remain valid unless changed.